Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia

Journal of Cellular Biochemistry

Volumn 96, Issue 4, 2005, Pages 665-671

  Tyagi, Neetu ^a   Moshal, Karni S ^a   Ovechkin, Alexander V ^a   Rodriguez, Walter ^a   Steed, Mesia ^a   Henderson, Brooke ^a   Roberts, Andrew M ^a   Joshua, Irving G ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

2K1C; Aortic stenosis; Arterial pressure; CBS; Collagen; Diastolic function; Elastin; Folic acid; MMP; Nitrotyrosine; NO; SAH; SAHH; SAM; SHR

Indexed keywords

3 NITROTYROSINE; ADENOSYLHOMOCYSTEINASE; CALCIUM ION; CALPAIN; COLLAGEN; CONTRACTILE PROTEIN; ELASTIN; HOMOCYSTEINE; METHIONINE; METHYLTRANSFERASE; NITRIC OXIDE SYNTHASE; PEROXIREDOXIN; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; THIOREDOXIN;

CYTOSKELETON; DNA METHYLATION; ENZYME ACTIVITY; HEART FAILURE; HEART WORK; HYPERHOMOCYSTEINEMIA; HYPERTENSION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASCULAR RESISTANCE;

HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 27644581655     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20578     Document Type: Review

References (53)

1. Audelin MC, Genest J, Jr. 2001. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 59(2):497-511.
2. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. 1990. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci 87(4):1620-1624.
3. Boers GHJ, Smals AGH, Trijbels FJM, Bakkeren JAJM, Schoonderwalt HC, Kloppenborg PWC. 1985. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Eng J Med 313:709-715.
4. Bosse HM, Bachmann S. 1997. Immunohistochemically detected protein nitration indicates sites of renal NO release in Goldblatt hypertension. Hypertension 30:948-952.
5. Bushehri N, Taylor S, Lieberan S, Mirdamadi-Zonozi N, Birkmayer G, Preuss HG. 1998. Oral reduced b-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR). Geriat Nephrol Urol 8:95-100.
6. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. 1998. Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 351:36-37.
7. Clarke R, Collins R. 1998. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 5(4):249-255.
8. Cuzzocrea S, Zingarelli B, Caputi AP. 1998. Role of peroxynitrite and poly (ADP-ribosyl) synthetase activation in cardiovascular derangement induced by zymosan in the rat. Life Sci 63(11):923-933.
9. Davey SG, Ebrahim S. 2003. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32(1):1-22.
10. Dudman NPB, Wilcken DEL. 1983. Increased plasma copper in patients with homocysteineurea due to cystathione beta synthase deficiency. Clin Chim Acta 127:105-113.
11. Fallon UB, Elwood P, Ben Shiomo Y, Ubbink JB, Greenwood R, Smith GD. 2001. Homocysteine and ischaemic stroke in men: The Caerphilly study. J Epidemiol Community Health 55(2):91-96.
12. Fallon UB, Virtamo J, Young I, et al. 2003. Homocysteine and cerebral infarction in Finnish male smokers. Stroke 34(6):1359-1363.
13. Faury G, Ristori MT, Verdetti J, Jacob MP, Robert L. 1995. Effect of elastin peptides on vascular tone. J Vasc Res 32:112-119.
14. Finkelstein JD. 1990. Methionine metabolism in mammals. J Nutr Biochem 1:228-237.
15. Finkelstein JD. 1998. The metabolism of Hcy: Pathways and regulation. Eur J Pediatr 157(S-2):S40-S44.
16. Fonseca VA, Fink UM, Kern PA. 2003. Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects. Atherosclerosis 167(1):105-109.
17. Graham IM, Daly LE, Refsum HM, et al. 1997. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project [see comments]. JAMA 277(22):1775-1781.
18. Hofmaim MA. 1999. Homocysteine induces vascular activation in vitro and in vivo accelerated atherosclerosis develops in apo E null mice with hyperhomocysteinemia. Circulation 100:1-44.
19. Homocysteine Studies Collaboration. 2002. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 23;288(16):2015-2022.
20. Horton JR, Udo WE, Precht P, Balakir R, Hasty K. 1998. Cytokine inducible MMP expression in immortalized rat chondrocytes is independent of NO stimulation. In Vitro Cell Dev Biol Anim 34:378-384.
21. Huie RE, Padjama S. 1993. The reaction of NO with superoxide. Free Radic Res Comm 18:195-199.
22. Johnson RA, Freeman RH. 1992. Sustained hypertension in the rat induced by chronic blockade of nitric oxide. Am J Hypertens 5:919-922.
23. Jourdheuil-Rahmani D, Rolland PH, Rosset E, Branchereau A, Garcon D. 1997. Homocyateine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors. Cardiovas Res 34:597-602.
24. Kaye JM, Stanton KG, McCann VJ, Vasikaran VB, Taylors RR, van Bockxmeer FM. 2002. Homocysteine, folate, methylene-tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clin Sci 102:631-637.
25. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. 2002. MTHFR 677C→T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 23;288(16):2023-2031.
26. Malinow MR, Levenson J, et al. 1995. Role of blood pressure, uric acid and hemorheological parameters on plasma homocysteine concentration. Atherosclerosis 114:175-183.
27. Martinez Ayala M, Vazquez CB, Sanchez Mendoza A, Cortes Garcia JC, Escalante Acosta BA. 1998. The effect of aortic coarctation on nitric oxide production by vascular endothelium. Arch del Instit de Cardiol de Mexico 68:289-294.
28. Matthias D, Becker CH, Riezler R, Kindling PH. 1996. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and SHR following application of high doses of methionine. Atherosclerosis 122:201-216.
29. McCully KS. 1996. Homocysteine and vascular disease. Nat Med 2:386-389.
30. Milstein S, Katusic Z. 1999. Oxidation of tetrahydrobiopterin by peroxinitrite: Implications for vascular endothelial function. Biochem Biophys Res Commun 263:681-684.
31. Mujumdar VS, Hayden MR, Tyagi SC. 2000. Homocysteine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 183:28-36.
32. Mujumdar VS, Aru GM, Tyagi SC. 2001. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 82(3):491-500.
33. Nygard O. 1997. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Eng J Med 337:230-236.
34. Nygard O, Vollset SE, et al. 1995. Total plasma homocysteine and cardiovascular risk profile. J Am Med Assoc 274:1526-1533.
35. Radomski A, Sawicki G, Olson DM, Radomski MW. 1998. The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br J Pharmacol 125:1455-1462.
36. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. 1996. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular MMP in vitro. J Clin Invest 98:2572-2579.
37. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Gujllou J, Charpioy P, Bodard H, Ghininghelli O, Calaf R, Luccioni R, Garcon D. 1995. Hyperhomocysteinemia-induced vascular damage in the minipigs. Circulation 91:1161-1174.
38. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M. 1998. Nitric oxide mediates IL-1 induced gene expression of MMPs and bFGF in cultured rabbit articular chondrocytes. J Biochem 123:431-439.
39. Schmidt HHHW, Lohmann SM, Walter U. 1993. The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action. Biochim Biophys Acta 1178:153-175.
40. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. 2002. Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: The Swiss Heart study: a randomized controlled trial. JAMA 28;288(8):973-979.
41. Sharma RV, Tan E, Fang S, Gurjar MV, Bhalla RC. 1999. NOS gene transfer inhibits expression of cell cycle regulatory molecules in vascular smooth muscle cells. Am J Physiol 276:H1450-H1459.
42. Shcherbak NS, Shutskaya ZV, Sheidina AM, Larionova VI, Schwartz EI. 1999. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol Genet Metab 68:375-378.
43. Simon DI, Mullins ME, Jia L, Gaston B, Singel DL, Stamler JS. 1996. Polynitrosylated proteins: Characterization, bioactivity and functional consequences. Proc Nati Acad Sci (USA) 93:4736-4741.
44. Sutton-Tyrrell K, Bostom A, Selhub J, Ziegler-Johson C. 1997. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96:1745-1749.
45. Toole JF, Malinow MR, Chambless LE, et al. 2004. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 4;291(5):565-575.
46. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh C-M, Harber E, Schiegel R, Lee M-E. 1994. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci (USA) 91:6369-6373.
47. Tyagi SC. 1998. Homocysteine re'dox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol 274:C396-C405.
48. Tyagi SC. 1999. Homocyst(e)ine and heart disease: Pathophysiology of extracellular matrix. Clin Exp Hypertens 21:181-198.
49. Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, Parker JL. 1998. Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in vascular extracellular matrix remodeling and vascular tone. Mol Cell Biochem 181:107-116.
50. Upchurch GR, Welch GN, Fabian AJ, et al. 1997a. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272:17012-17017.
51. Upchurch GR, Jr., Welch GN, Fabian AJ, Pigazzi A, Keaney JF, Jr., Loscalzo J. 1997b. Stimulation of endothelial nitric oxide production by homocysteine. Atherosclerosis 132:177-185.
52. Wollesen F, Brattstrom L, Refsum H, et al. 1999. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55:1028-1035.
53. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. 2000. Increase in plasma homocysteine associated with parallel increase in plasma s-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 275:29318-29323.